{"id":"venlafaxinexr","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Nausea"},{"rate":"15-25%","effect":"Headache"},{"rate":"10-20%","effect":"Dizziness"},{"rate":"10-15%","effect":"Insomnia"},{"rate":"10-15%","effect":"Somnolence"},{"rate":"10-15%","effect":"Sweating"},{"rate":"10-15%","effect":"Sexual dysfunction"},{"rate":"3-5%","effect":"Hypertension"},{"rate":"5-10%","effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that blocks the reuptake transporters for both serotonin and norepinephrine, leading to increased neurotransmitter concentrations in the synapse. At lower doses it preferentially inhibits serotonin reuptake, while at higher doses it also significantly inhibits norepinephrine reuptake. The extended-release (XR) formulation provides sustained drug levels throughout the day.","oneSentence":"Venlafaxine XR inhibits the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:06.858Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"},{"name":"Social anxiety disorder"},{"name":"Panic disorder"},{"name":"Vasomotor symptoms associated with menopause"}]},"trialDetails":[{"nctId":"NCT00021528","phase":"PHASE4","title":"Sequenced Treatment Alternatives to Relieve Depression (STAR*D)","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2001-07","conditions":"Depression","enrollment":4000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"VenlafaxineXR","genericName":"VenlafaxineXR","companyName":"National Institute of Mental Health (NIMH)","companyId":"national-institute-of-mental-health-nimh","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venlafaxine XR is a medication used to treat depression, as indicated by ClinicalTrials.gov. Its mechanism of action is not specified in the provided facts, but it is listed as an intervention in various clinical trials, including the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}